Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 3/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 7/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.39 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.39 |
| ▸ | GCGR | P47871 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | TDP2 | O95551 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6500949 | 0.93 | BCL2 (0.54) | BCL2MCL1MRGPRX4PLA2G4BPLA2G2A | |
| SCHEMBL6490528 | 0.84 | DCTPP1 (0.42) | MRGPRX4DCTPP1PPARG | |
| SCHEMBL6501700 | 0.83 | MCL1 (0.40) | BCL2MCL1PPARG | |
| SCHEMBL6502208 | 0.83 | MCL1 (0.44) | BCL2MCL1MRGPRX4PPARG | |
| SCHEMBL6496934 | 0.82 | MCL1 (0.54) | BCL2MCL1PLA2G2A | |
| SCHEMBL7194322 | 0.82 | BCL2 (0.48) | BCL2MCL1MRGPRX4PLA2G2A | |
| SCHEMBL6490840 | 0.82 | BCL2 (0.46) | BCL2MCL1PLA2G2APPARG | |
| SCHEMBL6488344 | 0.82 | MCL1 (0.47) | MCL1PLA2G4BPLA2G2APPARG | |
| SCHEMBL6500130 | 0.81 | DCTPP1 (0.47) | BCL2MCL1DCTPP1PPARG | |
| SCHEMBL6489915 | 0.80 | NR4A2 (0.46) | MRGPRX4DCTPP1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | BCL2 774/4885MCL1 806/4885MRGPRX4 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.